DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)

Q: What does CUSIP 25253X207 represent in this 13F holders report?

CUSIP 25253X207 is the security identifier for DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value used to aggregate holder disclosures.

Q: How many institutions held DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in Q4 2025?

92 institutional investors reported DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 25253X207

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Voting Common Shares, no par value
Shares outstanding: 52,272,727
Total 13F shares: 12,053,996
Share change: -796,042
Total reported value: $95,986,433
Put/Call ratio: 85%
Price per share: $7.96
Number of holders: 92
Value change: -$5,768,433
Number of buys: 54
Number of sells: 26

Quarterly Holders Quick Answers

What is CUSIP 25253X207?
CUSIP 25253X207 identifies DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 25253X207:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Jan Stahlberg	3/4/5	10%+ Owner	17%	8,825,742	$75,679,855	+$18,989,576	17 Nov 2025	3/4/5
TRILL AB	13D/G	—	17%	8,825,742	$70,252,906	+$8,447,765	31 Dec 2025	13D/G
Richard Jacinto II	13D/G 3/4/5	10%+ Owner	9.6%	4,958,823	$34,067,114	$0	30 Sep 2025	13D/G 3/4/5
TomEnterprise AB	13D/G	—	16%	8,383,577	$32,695,950	$0	23 Jul 2025	13D/G
Thomas von Koch	3/4/5	10%+ Owner	16%	8,383,577	$29,342,519	+$9,999,997	23 Jul 2025	3/4/5
Leon G. Cooperman	13D/G 13F	Cooperman Leon G. · Individual	6.6%	3,450,000	$28,462,500	+$1,486,972	31 Dec 2025	13D/G 13F
BlackRock, Inc.	13F	Company	3.2%	1,678,139	$11,528,816	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	2.3%	1,187,309	$8,156,813	—	30 Sep 2025	13F
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE	13F	Company	1.7%	875,000	$6,011,250	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.4%	711,818	$4,891,114	—	30 Sep 2025	13F
VANGUARD GROUP INC	13F	Company	1.3%	664,575	$4,565,630	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	1.1%	579,585	$3,981,749	—	30 Sep 2025	13F
FIRST MANHATTAN CO. LLC.	13F	Company	0.97%	505,000	$3,469,350	—	30 Sep 2025	13F
David J. Wambeke	3/4/5	Chief Business Officer	— mixed-class rows	1,304,228 mixed-class rows	$3,420,969	—	01 Jun 2025	3/4/5
STATE STREET CORP	13F	Company	0.91%	476,583	$3,274,125	—	30 Sep 2025	13F
Bleichroeder LP	13F	Company	0.73%	382,317	$2,626,518	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.65%	339,578	$2,332,901	—	30 Sep 2025	13F
Richard D. Pilnik	3/4/5	Director	— class O/S missing	591,597	$1,440,505	—	07 Apr 2025	3/4/5
LPL Financial LLC	13F	Company	0.39%	203,150	$1,395,641	—	30 Sep 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.35%	182,305	$1,253,699	—	30 Sep 2025	13F
Corient Private Wealth LLC	13F	Company	0.27%	140,000	$961,800	—	30 Sep 2025	13F
Corient IA LLC	13F	Company	0.25%	132,500	$910,275	—	30 Sep 2025	13F
CANTOR FITZGERALD, L. P.	13F	Individual	0.19%	100,000	$687,000	—	30 Sep 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.18%	92,427	$634,973	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.15%	77,292	$530,996	—	30 Sep 2025	13F
Nuveen, LLC	13F	Company	0.14%	74,667	$512,962	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.13%	69,352	$476,448	—	30 Sep 2025	13F
Blue Trust, Inc.	13F	Company	0.13%	69,122	$474,868	—	30 Sep 2025	13F
Bank of New York Mellon Corp	13F	Company	0.13%	68,941	$473,621	—	30 Sep 2025	13F
Dietrich John Pauls	3/4/5	President & CEO, Director	— mixed-class rows	737,182 mixed-class rows	$445,155	—	01 Jun 2025	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.11%	57,546	$395,341	—	30 Sep 2025	13F
Meridian Wealth Management, LLC	13F	Company	0.1%	51,666	$354,945	—	30 Sep 2025	13F
Private Capital Management, LLC	13F	Company	0.1%	50,000	$343,500	—	30 Sep 2025	13F
BARCLAYS PLC	13F	Company	0.09%	45,440	$312,173	—	30 Sep 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.08%	41,930	$288,000	—	30 Sep 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.08%	39,549	$271,702	—	30 Sep 2025	13F
MARSHALL WACE, LLP	13F	Company	0.07%	39,062	$268,356	—	30 Sep 2025	13F
Creative Planning	13F	Company	0.07%	38,790	$266,487	—	30 Sep 2025	13F
CATALYST FINANCIAL PARTNERS LLC	13F	Company	0.07%	38,457	$264,200	—	30 Sep 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0.07%	36,501	$250,761	—	30 Sep 2025	13F
World Investment Advisors	13F	Company	0.07%	34,325	$235,813	—	30 Sep 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.06%	32,767	$225,109	—	30 Sep 2025	13F
Scott Kellen	3/4/5	CFO & Secretary	— mixed-class rows	289,580 mixed-class rows	$209,562	—	01 Jun 2025	3/4/5
Amy L. Burroughs	3/4/5	Director	— class O/S missing	73,288	$205,206	—	03 Jan 2023	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.05%	28,367	$194,881	—	30 Sep 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.05%	27,451	$188,588	—	30 Sep 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.05%	27,357	$187,938	—	30 Sep 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.04%	21,947	$150,777	—	30 Sep 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.04%	19,660	$136,000	—	30 Sep 2025	13F
Man Group plc	13F	Company	0.04%	19,414	$133,374	—	30 Sep 2025	13F

Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q4 2025

As of 31 Dec 2025, DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) was held by 92 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 12,053,996 shares. The largest 10 holders included COOPERMAN LEON G, BlackRock, Inc., PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, STATE STREET CORP, MORGAN STANLEY, FIRST MANHATTAN CO. LLC., and Bleichroeder LP. This page lists 92 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.